Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes

作者：Huili Zhu, Bin Yang, Longyan Lu, Yufeng Li, Rubo Sui, Kewei Liu, Suling Tan, Lihua Wang, Jianmin Qiu, Jianbin Zhong, Tongguo Wei, Yuzhang Bei, Jianmin Huang, Suping Zhang, Yan Ji, Wenjun Wu, Youjia Li, Ying Huang, Yang‐Kun Chen, Xiaoyun Huang, Guoyong Zeng, Yusheng Zhang, Lian Huang, Hao Li, Xiangbing Wang, Yongjun Wang, Anding Xu, LAMP Investigators, Wenyan Zhuo, Qingyu Shen, Jian Xia, Zhen-Gang Cha, Liangping Luo, Zhan-Yu Cai, Aidong Zhang, Shengming Liu, Yi Zhou, Xiao-Min Xiao, Yueping Liu, Haiping Jiang, Weiju Chen, Bin Li, Xiaosong Wu, Dongxia Wu, Shaohua Chen, Yiping Qiu, Guohua Chen, Juan Wang, Shen Zheng, David Wang, An-Xin Wang, Jun Lyu, Yansheng Li, Kangning Chen, Bo Hu, Yongshun Zhang, Qiao-Wei Li, Wei-Jian Xie, Ji Liang, Shuixiang He · 发表于：JAMA Internal Medicine · 年份：2025 · DOI：10.1001/jamainternmed.2025.5684 · 被引用次数：7 · 研究领域：Diabetes Treatment and Management、Heart Failure Treatment and Management、Acute Ischemic Stroke Management

Importance: Glucagon-like peptide-1 receptor agonists can reduce the risk of cardiovascular events in patients with high-risk type 2 diabetes (T2D). However, dedicated randomized clinical trials that evaluate their efficacy in acute ischemic stroke are lacking. Objective: To investigate the safety and efficacy of liraglutide in patients with T2D and minor acute ischemic stroke (AIS) or high-risk transient ischemic attack (TIA). Design, Setting, and Participants: The LAMP trial was designed as a multicenter, controlled, prospective, randomized, open-label, blinded end point trial and conducted at 27 hospitals in China from June 25, 2019, through December 27, 2023. The final follow-up was on March 24, 2024. Data were analyzed on May 1, 2024. The study included patients with T2D who had minor AIS (National Institutes of Health Stroke Scale score ≤3) or high-risk TIA (ABCD2 score [age, blood pressure elevation on first assessment after TIA, unilateral weakness, speech disturbance, duration of symptoms and diabetes] ≥4). Interventions: Eligible patients were randomized within 24 hours of symptom onset to the liraglutide group and the control group. Both groups received standard treatment according to the guidelines. The liraglutide group received liraglutide once daily for 90 days (0.6 mg for the first week, which was increased to 1.2 mg in the second week and followed by 1.8 mg until day 90) in addition to standard therapy. Main Outcomes and Measures: The primary outcome was stro...